Szerző szerinti böngészés "Halasi, Barbara Dora"
Megjelenítve 1 - 10 (Összesen 10)
Találat egy oldalon
Rendezési lehetőségek
Tétel Korlátozottan hozzáférhető Antihyperlipidemic drugs and their role in DM and it's complicationsAverbuch, Galit; Pórszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Halasi, Barbara Dora; Szentmiklósi, József; Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetAntilipidemic drugs are used to treat hypercholesterolemia and dyslipidemias. They are usually used long term and often in combination. This review shows updated data on current and new antihyperlipidemic drugs. Their use strategies and clinical management of diabetes and its complications. As well as their role in their prevention.Tétel Korlátozottan hozzáférhető Current status and future of immunotherapy in non-small cell lung cancerTsai, Ping Lien; Megyeri, Attila; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Szentmiklósi, József; Halasi, Barbara Dora; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Általános Orvostudományi Kar::Igazságügyi Orvostani IntézetAround 85% of lung cancer cases are non-small cell lung cancer (NSCLC). Recent treatment used for NSCLC has been changed to immunotherapy, especially immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 and CTLA-4 inhibitors. These treatments increase the overall survival (OS) and progression-free survival (PFS) of patients.Tétel Korlátozottan hozzáférhető Pharmacologial Aspects of Metabolic Syndrome.Jo, Sua; Pórszász, Róbert; Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Szentmiklósi, József András; Halasi, Barbara Dora; Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Debreceni Egyetem::Általános Orvostudományi Kar::Igazságügyi Orvostani IntézetThe thesis discusses mainly about the metabolic syndrome and its subcategories. The subcategories consists of Insulin Resistance, Central Obesity, Hypertension and Dyslipidemia. The thesis first briefly mention the etiologies and risk factors, symptoms, diagnosis but focuses mainly on the treatment, especially emphasizing the pharmacological drugs. When discussing about the pharmacological aspects of the diseases, it is written based on their mechanisms of action, contraindications, and adverse effects. Finally, the thesis further goes through the intimate relationships between these diseases showing how they affects each other and the common indications of their drugs.Tétel Korlátozottan hozzáférhető Pharmacological interventions in head and neck tumorsYokoi, Konatsu; Porszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Megyeri, Attila; Halasi, Barbara Dora; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Általános Orvostudományi Kar::Igazságügyi Orvostani IntézetThis thesis examines the role of systemic therapies in head and neck tumors, focusing on cytotoxic chemotherapy, targeted therapies, and immunotherapy. The mechanisms, efficacy, and toxicity of chemotherapeutic agents such as alkylating agents, antimetabolites, and microtubule inhibitors are analyzed. Additionally, targeted therapies, including EGFR and VEGF inhibitors, as well as molecularly targeted agents affecting MET, mTOR, and EGFR pathways, are explored. The study also highlights immunotherapeutic approaches, particularly PD-1, PD-L1, and CTLA-4 inhibitors, as well as novel treatments such as cancer vaccines and adoptive cell transfer.Tétel Korlátozottan hozzáférhető Pharmacological Management of Ventricular ExtrasystolesPhan, Le Phuc Tuong; Porszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Halasi, Barbara Dora; Szentmiklósi, József; Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetThis thesis provides a comprehensive and well-structured examination of the pharmacological management of ventricular extrasystoles (VEs). It effectively outlines the pathophysiology, classification, and clinical significance of VEs, establishing a strong foundation for the subsequent discussion on treatment strategies. The core of the work is a detailed analysis of antiarrhythmic drugs, systematically categorized by the Vaughan-Williams classification, which is thorough and informative. The thesis successfully integrates clinical insights and evidence-based findings to emphasize the need for a tailored approach to patient care, making it a well-rounded piece of scholarly work. The conclusion thoughtfully summarizes the key takeaways, reinforcing the importance of a holistic management strategy for VEs.Tétel Korlátozottan hozzáférhető Pharmacological Therapy Of Acne VulgarisAl-obaidi, Zahraa; Pórszász , Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Szentmiklosi, József; Halasi, Barbara Dóra; Halasi, Barbara Dora; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Általános Orvostudományi Kar::Igazságügyi Orvostani IntézetThe thesis titled “Pharmacological Therapy of Acne Vulgaris” explores the causes, types, and modern treatments of acne. It describes acne as a persistent inflammatory disorder of the skin’s pilosebaceous unit, mainly influenced by hormones, bacteria, and immune activity. The research reviews both topical medications—such as retinoids, benzoyl peroxide, and antibiotics—and systemic options, including oral antibiotics, hormonal agents, and isotretinoin, with attention to their actions and side effects. It emphasizes the value of evidence-based, personalized therapy guided by international recommendations. The study also addresses treatment considerations during pregnancy, the emotional and psychological burden of acne, and the issue of antibiotic resistance. Finally, it highlights innovative approaches like microbiome-focused therapy, probiotics, and nanotechnology as promising directions for future acne management.Tétel Korlátozottan hozzáférhető Pharmacology of Banned Performance-Enhancing DrugsBaltinester, Noam; Pórszász, Róbert; Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Halasi, Barbara Dora; Szentmiklósi, József András; Debreceni Egyetem::Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet; Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetPerformane-enhancing drugs, aka PEDs, are a grouping of several classes of drugs which are known to enhance athletic performance and are therefore their use has been baned. This thesis explored the pharmacology of a handful of PEDs. Making use of various studies, case reports, and litterature reviews, we looked into the pharmacokinetics, pharmacodynamics, and adverse effects of various PEDs, as well as some other aspects of their use. Along with this, a brief history of PED use as well as ethical and legal aspects were discussed.Tétel Korlátozottan hozzáférhető Pharmacotherapy of Duchenne Muscular Dystrophy (DMD)Poornachandran, Deepti Nirja; Porszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Megyeri, Attila; Halasi, Barbara Dora; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Általános Orvostudományi Kar::Igazságügyi Orvostani IntézetDuchenne Muscular Dystrophy (DMD) is a severe, progressive neuromuscular disorder caused by mutations in the DMD gene, leading to the absence of functional dystrophin protein. Over time, it results in muscle weakness and degeneration, causing loss of mobility, respiratory failure, and ultimately, death. This necessitates the need for effective pharmacotherapy to slow the disease progression and improve patient outcomes. The review discusses corticosteroids, which are the gold standard for treating the downstream pathological changes seen in DMD. Novel therapies such as exon skipping, stop codon readthrough, and gene therapies have proven to be reliable in treating some, if not all, mutation variants. With advancements in medical research and technologies, we can hope for better disease management and extended life expectancy.Tétel Korlátozottan hozzáférhető Prevention And Pharmacological Management Of ArrythmiaAhmad, Mostafa; Porszász, Róbert; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Halasi, Barbara Dora; Szentmiklósi, József; Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet; Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai IntézetThis paper discusses arrhythmias and their myriad of causes. Topics such as incidence and prevalence in the population are also discussed. Global patterns and future trends are mentioned in regards to arrhythmia. The treatment for arrhythmia whether it be conservative or pharmacological is also mentioned. The different types of medication is distinguished in the discussion of the topic.Tétel Korlátozottan hozzáférhető The role of SSRIs in the treatment of unipolar depressionHaji Heidari Varnousafaderani, Mahsa; Pórszász, Róbert; Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; DE--Általános Orvostudományi Kar; Szentmiklósi, József András; Halasi, Barbara Dora; Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet; Debreceni Egyetem::Általános Orvostudományi Kar::Igazságügyi Orvostani IntézetThe therapeutic indications for SSRIs, adverse effect profiles, variations among classes, and possible associations with SI were all covered in this study. SSRIs were first used to treat depressive disorders, such as unipolar depression, but they are now also used to treat anxiety disorders, other mental illnesses, and a few physical ailments. Depending on the comorbidities, genetics, and probable side effects of the patient, each SSRI has distinct qualities which render it a better match for certain persons. Patients who require multiple pharmacologic treatments for various conditions may benefit from considering an SSRI like citalopram or escitalopram that does not inhibit cytochrome P450 enzymes, as this can help prevent potential drug-drug interactions. Although SSRIs are far more well tolerated than MAOIs and TCAs that came before them, there are still some possible side effects. A few of the most typical ones include sexual dysfunction, GI discomfort, sleeplessness, and irritability. The black box warning for a higher probability of SI in children and young people aged 18 to 24 is one of the most contentious side effects of SSRIs. The intricacies and interactions of SSRIs in a depressed young person's growing brain are poorly understood. Adults without particular risk characteristics, as previously mentioned, do not seem to be at elevated risk of suicidality. In the end, a risk-benefit analysis must take the possible effects of the condition to be treated, side effects, and risks into account before prescribing SSRIs to any patient.